Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

EMPACTA
  NCT04372186		 RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
259/129 conclusif 12% 13% demonstrated-40%
NCT04412772 (ARCHITECTS) unpublished
  NCT04412772		 RCTtocilizumab placeboCOVID 19 hospitalizedlow
10/11 inconclusive -74%

COVID 19 all comers meta-analysis

BACC Bay Tocilizumab Trial
  NCT04356937		 RCTtocilizumab placeboCOVID 19 all comerslow
161/81 inconclusive 47% 5% -15%

COVID-19 severe or critically meta-analysis

Rosas (REMDACTA)
  NCT04409262		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
434/215 inconclusive -5% -2%
COVACTA (Rosas)
  NCT04320615		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
301/151 suggested 25% 17%
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons